Ziv Paz1, George C Tsokos. 1. Division of Rheumatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. zpaz@bidmc.harvard.edu
Abstract
PURPOSE OF REVIEW: The purpose of this review is to discuss new therapeutics in systemic lupus erythematosus (SLE). We will concentrate on both approved and unapproved treatments that were published during the last year. RECENT FINDINGS: Efforts have focused on the optimization of the use of Belimumab and Rituximab using information generated previously in clinical trials and the development of small new drugs inhibitors of the proteasome and immune cell signaling molecules such as Btk, ROCK and CaMK4. We cannot predict which biologics are going to be effective in humans, as many of the biologics that provide significant benefit in preclinical trials and lupus-prone mice have often proved noneffective in clinical trials. We now realize that lupus-prone mice do not represent human SLE. Yet, genetic or treatments studies in mice are valuable and help us to understand the role of immune or biochemical abnormalities identified in patients in a whole organism. SUMMARY: 2012 was an exciting year for the field of novel therapeutics in SLE and was signified by the effort to target specific signaling pathways with small molecules and biological agents.
PURPOSE OF REVIEW: The purpose of this review is to discuss new therapeutics in systemic lupus erythematosus (SLE). We will concentrate on both approved and unapproved treatments that were published during the last year. RECENT FINDINGS: Efforts have focused on the optimization of the use of Belimumab and Rituximab using information generated previously in clinical trials and the development of small new drugs inhibitors of the proteasome and immune cell signaling molecules such as Btk, ROCK and CaMK4. We cannot predict which biologics are going to be effective in humans, as many of the biologics that provide significant benefit in preclinical trials and lupus-prone mice have often proved noneffective in clinical trials. We now realize that lupus-prone mice do not represent humanSLE. Yet, genetic or treatments studies in mice are valuable and help us to understand the role of immune or biochemical abnormalities identified in patients in a whole organism. SUMMARY: 2012 was an exciting year for the field of novel therapeutics in SLE and was signified by the effort to target specific signaling pathways with small molecules and biological agents.
Authors: Paola Pinheiro Kahwage; Mariana Paes Leme Ferriani; João M Furtado; Luciana Martins de Carvalho; Gecilmara Salviato Pileggi; Francisco Hugo Rodrigues Gomes; Maria Teresa Terreri; Claudia Saad Magalhães; Rosa Maria Rodrigues Pereira; Silvana Brasilia Sacchetti; Roberto Marini; Eloisa Bonfá; Clovis Artur Silva; Virgínia Paes Leme Ferriani Journal: Clin Rheumatol Date: 2017-01-09 Impact factor: 2.980
Authors: Luca Petricca; Maria Rita Gigante; Annamaria Paglionico; Stefano Costanzi; Gisella Vischini; Clara Di Mario; Valentina Varriano; Giacomo Tanti; Barbara Tolusso; Stefano Alivernini; Giuseppe Grandaliano; Gianfranco Ferraccioli; Elisa Gremese Journal: Front Med (Lausanne) Date: 2020-10-28